Miniatura

Fitxers

MoserleL.pdf (158.55 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2012-03-01

Llicència de publicació

cc by (c) Moserle, Lidia; Casanovas Casanovas, Oriol, 2012
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126532

Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/emmm.201200206

Resum

Semaphorins (SEMAs) are a superfamily of secreted or membrane‐associated glycoproteins implicated in the control of axonal wiring and involved in angiogenesis and cancer progression. Class‐3 SEMAs are the only secreted vertebrate SEMAs and several of them are regulated by protease‐mediated cleavage (Capparuccia & Tamagnone, 2009). Their high‐affinity receptors, Plexins and co‐receptor Neuropilins, are expressed in a wide variety of cell types including endothelial and tumour cells. Plexins show an intrinsic R‐Ras GAP activity, but interestingly also form complexes with additional transmembrane molecules, including certain receptor tyrosine kinases (RTKs) such as c‐Met, ErbB2 and vascular endothelial growth factor receptor 2 (VEGFR2), that are transactivated by Plexins and initiate critical signalling pathways. These functional interactions with transactivated kinase receptors are key to define the cellular activities of SEMAs and convert the SEMAs into pleiotropic molecules. Thus, SEMAs can positively or negatively modulate many intrinsic properties of tumour cells, such as proliferation, cell survival, alteration in cell adhesion and tumour invasiveness, but also modulate several stromal components including endothelial cell migration and survival (Capparuccia & Tamagnone, 2009; Serini et al, 2009)...

Matèries

Glicoproteïnes, Càncer

Matèries (anglès)

Glycoproteins, Cancer

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

MOSERLE, Lidia, CASANOVAS I CASANOVAS, Oriol. Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer. _EMBO Molecular Medicine_. 2012. Vol. 4, núm. 3, pàgs. 168-170. [consulta: 21 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/126532]

Exportar metadades

JSON - METS

Compartir registre